Anlon Healthcare Limited has successfully completed the acquisition of 67.48% equity shareholding in Apiqo Organics Private Limited (formerly M/s Apple Life Science) as of January 9, 2026. This strategic move, initiated by a Share Purchase Agreement dated December 2, 2025, has resulted in Apiqo Organics becoming a subsidiary of Anlon Healthcare.

The company has confirmed that this investment and acquisition are in full compliance with Sections 179 (3) (e) & (j) and other relevant provisions of the Companies Act, 2013. All necessary details, as mandated by SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, were previously disclosed on December 2, 2025, following the execution of the Share Purchase Agreement.